Country: Unjoni Ewropea
Lingwa: Ingliż
Sors: EMA (European Medicines Agency)
mitratapide
Janssen Pharmaceutica N.V.
QA08AB90
mitratapide
Dogs
Antiobesity preparations, excl. diet products
As an aid in the management of overweight and obesity in adult dogs. To be used as part of an overall weight management programme which also includes appropriate dietary changes. Introducing appropriate lifestyle changes (e.g. increased exercise), in conjunction with this weight management programme, may provide additional benefits.
Revision: 3
Withdrawn
2006-11-14
Medicinal product no longer authorised B. PACKAGE LEAFLET 16/20 Medicinal product no longer authorised PACKAGE LEAFLET YARVITAN 5 MG/ML ORAL SOLUTION FOR DOGS Read all of this leaflet carefull y before you start administering the medicine to your dog: _Keep this leaflet. You may need to read it again _ _If you have further questions, please ask your veterinary surgeon or your pharmacist _ _This medicine has been prescribed for your dog only and you should not pass it on to others._ 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT Janssen Pharmaceutica N.V. Turnhoutseweg 30 B-2340 Beerse Belgium 2. NAME OF THE VETERINARY MEDICINAL PRODUCT Yarvitan 5 mg/ml oral solution for dogs Mitratapide 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Mitratapide 5 mg/ml Butylated hydroxyanisole (E 320) Yarvitan is a colourless to slightly yellow solution. 4. INDICATION(S) Yarvitan is indicated as an aid in the management of overweight and obesity in adult dogs. The treatment is part of an overall weight management programme which also includes a nutrition programme. Introducing appropriate lifestyle changes (e.g. increased exercise), in conjunction with this weight management programme, may provide additional benefits. 5. CONTRAINDICATIONS Do not administer Yarvitan: if your dog has impaired liver function. if your dog is hypersensitive (allergic) to mitratapide or to any of the other ingredients. if your dog is pregnant or during lactation. in dogs less than 18 months of age. if overweight or obesity in your dog is caused by a concomitant systemic disease such as hypothyroidism (this is due to a malfunction of the thyroid gland) or hyperadrenocorticism.(this is due to a malfunction of the adrenal gland). 17/20 Medicinal product no longer authorised 6. ADVERSE REACTIONS Tell your veterinary surgeon if you notice any of the following: significant loss of appetite. Loss of appetite Aqra d-dokument sħiħ
Medicinal product no longer authorised _ _ ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/20 Medicinal product no longer authorised 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Yarvitan 5 mg/ml oral solution for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE SUBSTANCE: Mitratapide 5 mg/ml EXCIPIENT(S): Butylated hydroxyanisole (E 320) 2 mg/ml For a full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Oral solution. A colourless to slightly yellow solution. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES As an aid in the management of overweight and obesity in adult dogs. To be used as part of an overall weight management programme which also includes appropriate dietary changes. Introducing appropriate lifestyle changes (e.g. increased exercise), in conjunction with this weight management programme, may provide additional benefits. 4.3 CONTRAINDICATIONS Do not use in dogs with impaired liver function. Do not use in case of hypersensitivity to the active substance or to any of the excipients. Do not use in dogs during pregnancy and lactation. Do not use in dogs less than 18 months of age. Do not use in dogs in which overweight or obesity is caused by a concomitant systemic disease such as hypothyroidism or hyperadrenocorticism. 4.4 SPECIAL WARNINGS None. 2/20 Medicinal product no longer authorised 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS The use in dogs for breeding purposes has not been evaluated. If vomiting, significantly reduced appetite or diarrhoea repeatedly occurs, treatment should be interrupted and the advice of a veterinarian should be sought. Where treatment is interrupted due to vomiting, it is recommended that when treatment is resumed, the product should be administered after a meal. In addition, treatment should be interrupted and the advice of a veterinarian should be sought where the observed body weight loss is severe and rapid. SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VE Aqra d-dokument sħiħ